Table of Contents

1 Study Coverage

• 1.1 Non-prescription Drugs Product
• 1.2 Market Segments
• 1.3 Key Manufacturers Covered
• 1.4 Market by Type
  • 1.4.1 Global Non-prescription Drugs Market Size Growth Rate by Product
  • 1.4.2 Brand Drugs
  • 1.4.3 Generic Drug
• 1.5 Market by End User
  • 1.5.1 Global Non-prescription Drugs Market Size Growth Rate by End User
  • 1.5.2 Hospital
  • 1.5.3 Clinic
  • 1.5.4 Other
• 1.6 Study Objectives
• 1.7 Years Considered

2 Executive Summary

• 2.1 Global Non-prescription Drugs Market Size
  • 2.1.1 Global Non-prescription Drugs Revenue 2014-2025
  • 2.1.2 Global Non-prescription Drugs Sales 2014-2025
• 2.2 Non-prescription Drugs Growth Rate by Regions
  • 2.2.1 Global Non-prescription Drugs Sales by Regions
  • 2.2.2 Global Non-prescription Drugs Revenue by Regions

3 Breakdown Data by Manufacturers

• 3.1 Non-prescription Drugs Sales by Manufacturers
  • 3.1.1 Non-prescription Drugs Sales by Manufacturers
  • 3.1.2 Non-prescription Drugs Sales Market Share by Manufacturers
  • 3.1.3 Global Non-prescription Drugs Market Concentration Ratio (CR5 and HHI)
• 3.2 Non-prescription Drugs Revenue by Manufacturers
  • 3.2.1 Non-prescription Drugs Revenue by Manufacturers (2014-2019)
  • 3.2.2 Non-prescription Drugs Revenue Share by Manufacturers (2014-2019)
• 3.3 Non-prescription Drugs Price by Manufacturers
• 3.4 Non-prescription Drugs Manufacturing Base Distribution, Product Types
  • 3.4.1 Non-prescription Drugs Manufacturers Manufacturing Base Distribution, Headquarters
  • 3.4.2 Manufacturers Non-prescription Drugs Product Type
  • 3.4.3 Date of International Manufacturers Enter into Non-prescription Drugs Market
• 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Product

• 4.1 Global Non-prescription Drugs Sales by Product
• 4.2 Global Non-prescription Drugs Revenue by Product
• 4.3 Non-prescription Drugs Price by Product

5 Breakdown Data by End User

• 5.1 Overview
• 5.2 Global Non-prescription Drugs Breakdown Data by End User

6 North America

• 6.1 North America Non-prescription Drugs by Countries
  • 6.1.1 North America Non-prescription Drugs Sales by Countries
  • 6.1.2 North America Non-prescription Drugs Revenue by Countries
  • 6.1.3 United States
  • 6.1.4 Canada
  • 6.1.5 Mexico
• 6.2 North America Non-prescription Drugs by Product
• 6.3 North America Non-prescription Drugs by End User

7 Europe

• 7.1 Europe Non-prescription Drugs by Countries
  • 7.1.1 Europe Non-prescription Drugs Sales by Countries
  • 7.1.2 Europe Non-prescription Drugs Revenue by Countries
  • 7.1.3 Germany
  • 7.1.4 France
  • 7.1.5 UK
  • 7.1.6 Italy
  • 7.1.7 Russia
• 7.2 Europe Non-prescription Drugs by Product
• 7.3 Europe Non-prescription Drugs by End User

8 Asia Pacific

• 8.1 Asia Pacific Non-prescription Drugs by Countries
  • 8.1.1 Asia Pacific Non-prescription Drugs Sales by Countries
  • 8.1.2 Asia Pacific Non-prescription Drugs Revenue by Countries
  • 8.1.3 China
  • 8.1.4 Japan
  • 8.1.5 Korea
  • 8.1.6 India
  • 8.1.7 Australia
  • 8.1.8 Indonesia
  • 8.1.9 Malaysia
  • 8.1.10 Philippines
  • 8.1.11 Thailand
  • 8.1.12 Vietnam
  • 8.1.13 Singapore
• 8.2 Asia Pacific Non-prescription Drugs by Product
• 8.3 Asia Pacific Non-prescription Drugs by End User

9 Central & South America

• 9.1 Central & South America Non-prescription Drugs by Countries
  • 9.1.1 Central & South America Non-prescription Drugs Sales by Countries
  • 9.1.2 Central & South America Non-prescription Drugs Revenue by Countries
  • 9.1.3 Brazil
• 9.2 Central & South America Non-prescription Drugs by Product
• 9.3 Central & South America Non-prescription Drugs by End User

10 Middle East and Africa

• 10.1 Middle East and Africa Non-prescription Drugs by Countries
  • 10.1.1 Middle East and Africa Non-prescription Drugs Sales by Countries
  • 10.1.2 Middle East and Africa Non-prescription Drugs Revenue by Countries
  • 10.1.3 GCC Countries
  • 10.1.4 Turkey
  • 10.1.5 Egypt
  • 10.1.6 South Africa
• 10.2 Middle East and Africa Non-prescription Drugs by Product
• 10.3 Middle East and Africa Non-prescription Drugs by End User

11 Company Profiles

• 11.1 Pfizer
  • 11.1.1 Pfizer Company Details
  • 11.1.2 Company Business Overview
  • 11.1.3 Pfizer Non-prescription Drugs Sales, Revenue and Gross Margin (2014-2019)
  • 11.1.4 Pfizer Non-prescription Drugs Products Offered
  • 11.1.5 Pfizer Recent Development
• 11.2 Roche
  • 11.2.1 Roche Company Details
  • 11.2.2 Company Business Overview
  • 11.2.3 Roche Non-prescription Drugs Sales, Revenue and Gross Margin (2014-2019)
  • 11.2.4 Roche Non-prescription Drugs Products Offered
  • 11.2.5 Roche Recent Development
• 11.3 Sanofi
  • 11.3.1 Sanofi Company Details
  • 11.3.2 Company Business Overview
  • 11.3.3 Sanofi Non-prescription Drugs Sales, Revenue and Gross Margin (2014-2019)
  • 11.3.4 Sanofi Non-prescription Drugs Products Offered
  • 11.3.5 Sanofi Recent Development
• 11.4 Johnson & Johnson
  • 11.4.1 Johnson & Johnson Company Details
  • 11.4.2 Company Business Overview
  • 11.4.3 Johnson & Johnson Non-prescription Drugs Sales, Revenue and Gross Margin (2014-2019)
  • 11.4.4 Johnson & Johnson Non-prescription Drugs Products Offered
  • 11.4.5 Johnson & Johnson Recent Development
• 11.5 Merck & Co. (MSD)
  • 11.5.1 Merck & Co. (MSD) Company Details
  • 11.5.2 Company Business Overview
  • 11.5.3 Merck & Co. (MSD) Non-prescription Drugs Sales, Revenue and Gross Margin (2014-2019)
  • 11.5.4 Merck & Co. (MSD) Non-prescription Drugs Products Offered
  • 11.5.5 Merck & Co. (MSD) Recent Development
• 11.6 Novartis
  • 11.6.1 Novartis Company Details
  • 11.6.2 Company Business Overview
  • 11.6.3 Novartis Non-prescription Drugs Sales, Revenue and Gross Margin (2014-2019)
  • 11.6.4 Novartis Non-prescription Drugs Products Offered
  • 11.6.5 Novartis Recent Development
• 11.7 AbbVie
  • 11.7.1 AbbVie Company Details
  • 11.7.2 Company Business Overview
  • 11.7.3 AbbVie Non-prescription Drugs Sales, Revenue and Gross Margin (2014-2019)
  • 11.7.4 AbbVie Non-prescription Drugs Products Offered
  • 11.7.5 AbbVie Recent Development
• 11.8 Gilead Sciences
  • 11.8.1 Gilead Sciences Company Details
  • 11.8.2 Company Business Overview
  • 11.8.3 Gilead Sciences Non-prescription Drugs Sales, Revenue and Gross Margin (2014-2019)
  • 11.8.4 Gilead Sciences Non-prescription Drugs Products Offered
  • 11.8.5 Gilead Sciences Recent Development
• 11.9 GlaxoSmithKline (GSK)
  • 11.9.1 GlaxoSmithKline (GSK) Company Details
  • 11.9.2 Company Business Overview
  • 11.9.3 GlaxoSmithKline (GSK) Non-prescription Drugs Sales, Revenue and Gross Margin (2014-2019)
  • 11.9.4 GlaxoSmithKline (GSK) Non-prescription Drugs Products Offered
  • 11.9.5 GlaxoSmithKline (GSK) Recent Development
• 11.10 Amgen
  • 11.10.1 Amgen Company Details
  • 11.10.2 Company Business Overview
  • 11.10.3 Amgen Non-prescription Drugs Sales, Revenue and Gross Margin (2014-2019)
  • 11.10.4 Amgen Non-prescription Drugs Products Offered
  • 11.10.5 Amgen Recent Development
• 11.11 AstraZeneca
• 11.12 Bristol-Myers Squibb
• 11.13 Eli Lilly
• 11.14 Teva
• 11.15 Bayer
• 11.16 Novo Nordisk
• 11.17 Allergan
• 11.18 Shire
• 11.19 Boehringer Ingelheim
• 11.20 Takeda

12 Future Forecast

• 12.1 Non-prescription Drugs Market Forecast by Regions
  • 12.1.1 Global Non-prescription Drugs Sales Forecast by Regions 2019-2025
  • 12.1.2 Global Non-prescription Drugs Revenue Forecast by Regions 2019-2025
• 12.2 Non-prescription Drugs Market Forecast by Product
  • 12.2.1 Global Non-prescription Drugs Sales Forecast by Product 2019-2025
  • 12.2.2 Global Non-prescription Drugs Revenue Forecast by Product 2019-2025
• 12.3 Non-prescription Drugs Market Forecast by End User
• 12.4 North America Non-prescription Drugs Forecast
• 12.5 Europe Non-prescription Drugs Forecast
• 12.6 Asia Pacific Non-prescription Drugs Forecast
• 12.7 Central & South America Non-prescription Drugs Forecast
• 12.8 Middle East and Africa Non-prescription Drugs Forecast

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

• 13.1 Market Opportunities and Drivers
• 13.2 Market Challenges
• 13.3 Market Risks/Restraints
• 13.4 Macroscopic Indicators

14 Value Chain and Sales Channels Analysis

• 14.1 Value Chain Analysis
• 14.2 Non-prescription Drugs Customers
• 14.3 Sales Channels Analysis
  • 14.3.1 Sales Channels
  • 14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix

• 16.1 Research Methodology
  • 16.1.1 Methodology/Research Approach
  • 16.1.2 Data Source
• 16.2 Author Details

A medication (also referred to as medicine, pharmaceutical drug, or simply drug) is a drug used to diagnose, cure, treat, or prevent disease. Drug therapy (pharmacotherapy) is an important part of the medical field and relies on the science of pharmacology for continual advancement and on pharmacy for appropriate management.
The global Non-prescription Drugs market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Non-prescription Drugs market based on company, product type, end user and key regions.

This report studies the global market size of Non-prescription Drugs in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Non-prescription Drugs in these regions.
This research report categorizes the global Non-prescription Drugs market by top players/brands, region, type and end user. This report also studies the global Non-prescription Drugs market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Pfizer
Roche
Sanofi
Johnson & Johnson
Merck & Co. (MSD)
Novartis
AbbVie
Gilead Sciences
GlaxoSmithKline (GSK)
Amgen
AstraZeneca
Bristol-Myers Squibb
Eli Lilly
Teva
Bayer
Novo Nordisk
Allergan
Shire
Boehringer Ingelheim
Takeda

Market size by Product
Brand Drugs
Generic Drug
Market size by End User
Hospital
Clinic
Other

Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa

The study objectives of this report are:
To study and analyze the global Non-prescription Drugs market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Non-prescription Drugs market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Non-prescription Drugs companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Non-prescription Drugs submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

In this study, the years considered to estimate the market size of Non-prescription Drugs are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025

This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Non-prescription Drugs market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.